Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label study to evaluate safety, tolerability and clinical utility of ULTRACET (37.5mg tramadol hydrochloride/325mg acetaminophen [tramadol/paracetamol]) for the treatment of breakthrough pain in cancer patients.

Trial Profile

An open label study to evaluate safety, tolerability and clinical utility of ULTRACET (37.5mg tramadol hydrochloride/325mg acetaminophen [tramadol/paracetamol]) for the treatment of breakthrough pain in cancer patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 May 2009

At a glance

  • Drugs Tramadol/paracetamol (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Johnson & Johnson
  • Most Recent Events

    • 06 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top